Nordic Drugs Announces CE Mark Approval for Lacrifill® Canalicular Gel, Introducing a New Treatment Option for Dry Eye in the Nordic Region
Malmö, Sweden – 14th of April 2025 – Nordic Drugs today announces that Lacrifill®, a novel therapy for the treatment of dry eye disease, has received CE mark approval. This regulatory milestone, achieved several months ahead of schedule, paves the way for market introduction across the Nordic region and other European countries in the coming months.
Lacrifill® is a cross-linked hyaluronic acid
